Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.

Torque Teno Virus (TTV) is a small, non-enveloped, single-stranded and circular DNA virus that infects the majority of the population worldwide. Increased levels of plasma TTV viral load have been observed in various situations of immune deficiency or dysregulation, and several studies have suggeste...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rémi Pescarmona, William Mouton, Thierry Walzer, Stéphane Dalle, Anaïs Eberhardt, Karen Brengel-Pesce, Marine Villard, Christine Lombard, Sophie Trouillet-Assant, Sébastien Viel
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/da99800be5be427dbf38058d00bced6f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da99800be5be427dbf38058d00bced6f
record_format	dspace
spelling	oai:doaj.org-article:da99800be5be427dbf38058d00bced6f2021-12-02T20:18:29ZEvaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.1932-620310.1371/journal.pone.0255972https://doaj.org/article/da99800be5be427dbf38058d00bced6f2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0255972https://doaj.org/toc/1932-6203Torque Teno Virus (TTV) is a small, non-enveloped, single-stranded and circular DNA virus that infects the majority of the population worldwide. Increased levels of plasma TTV viral load have been observed in various situations of immune deficiency or dysregulation, and several studies have suggested that TTV levels may be inversely correlated with immune competence. The measurement of TTV viremia by qPCR has been proposed as a potential biomarker for the follow-up of functional immune competence in immunosuppressed individuals, particularly hematopoietic stem cell transplant recipients. We hypothesized that TTV viral load could be used as a prognostic marker of immune checkpoint inhibitor (ICI) efficacy, and therefore investigated the TTV viral load in melanoma patients treated with nivolumab or pembrolizumab before and after 6 months of treatment. In the present study, TTV viral load was not different in melanoma patients before anti-PD-1 introduction compared to healthy volunteers, was not modified by ICI treatment and did not allowed to distinguish patients with treatment-sensitive tumor from patients with treatment-resistant tumor.Rémi PescarmonaWilliam MoutonThierry WalzerStéphane DalleAnaïs EberhardtKaren Brengel-PesceMarine VillardChristine LombardSophie Trouillet-AssantSébastien VielPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0255972 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rémi Pescarmona William Mouton Thierry Walzer Stéphane Dalle Anaïs Eberhardt Karen Brengel-Pesce Marine Villard Christine Lombard Sophie Trouillet-Assant Sébastien Viel Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.
description	Torque Teno Virus (TTV) is a small, non-enveloped, single-stranded and circular DNA virus that infects the majority of the population worldwide. Increased levels of plasma TTV viral load have been observed in various situations of immune deficiency or dysregulation, and several studies have suggested that TTV levels may be inversely correlated with immune competence. The measurement of TTV viremia by qPCR has been proposed as a potential biomarker for the follow-up of functional immune competence in immunosuppressed individuals, particularly hematopoietic stem cell transplant recipients. We hypothesized that TTV viral load could be used as a prognostic marker of immune checkpoint inhibitor (ICI) efficacy, and therefore investigated the TTV viral load in melanoma patients treated with nivolumab or pembrolizumab before and after 6 months of treatment. In the present study, TTV viral load was not different in melanoma patients before anti-PD-1 introduction compared to healthy volunteers, was not modified by ICI treatment and did not allowed to distinguish patients with treatment-sensitive tumor from patients with treatment-resistant tumor.
format	article
author	Rémi Pescarmona William Mouton Thierry Walzer Stéphane Dalle Anaïs Eberhardt Karen Brengel-Pesce Marine Villard Christine Lombard Sophie Trouillet-Assant Sébastien Viel
author_facet	Rémi Pescarmona William Mouton Thierry Walzer Stéphane Dalle Anaïs Eberhardt Karen Brengel-Pesce Marine Villard Christine Lombard Sophie Trouillet-Assant Sébastien Viel
author_sort	Rémi Pescarmona
title	Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.
title_short	Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.
title_full	Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.
title_fullStr	Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.
title_full_unstemmed	Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.
title_sort	evaluation of ttv replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/da99800be5be427dbf38058d00bced6f
work_keys_str_mv	AT remipescarmona evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients AT williammouton evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients AT thierrywalzer evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients AT stephanedalle evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients AT anaiseberhardt evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients AT karenbrengelpesce evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients AT marinevillard evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients AT christinelombard evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients AT sophietrouilletassant evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients AT sebastienviel evaluationofttvreplicationasabiomarkerofimmunecheckpointinhibitorsefficacyinmelanomapatients
_version_	1718374316068831232

Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients.

Ejemplares similares